ArteraAI Prostate Test

The first and only AI test to be recommended in the NCCN Clinical Guidelines in Oncology (NCCN Guidelines®) for Prostate Cancer for predictive and prognostic performance*

What is the ArteraAI prostate test?

 

The ArteraAI Prostate Test is a multimodal artificial intelligence (MMAI) biomarker test that assesses digital images from a patient’s prostate biopsy and learns from clinical data to predict whether a patient will benefit from hormone therapy and estimates long-term outcomes.

Who is the ArteraAI prostate test for?

 

The ArteraAI Prostate Test is recommended for use in patients who have been diagnosed with localized prostate cancer and who have not received hormone therapy prior to their prostate biopsy.

The test is meant to identify if the localized prostate cancer patient would benefit from increased hormone therapy.

The ArteraAI Prostate Test does not consume additional tissue and conditional test ordering is available for current pathology clients

  • 24-hour turnaround time
  • No need to ship slide
  • Combined pathology report
  • Recommended in NCCN guidelines*

Seamless Ordering with PathNet Partners

Combined Pathology Reports

A single report comprising diagnostic, prognostic, and predictive information, provided to the patient’s medical specialist.

  • Better Care
  • Improved Workflow
  • Enhanced Trust
See a Pathology Report

The ArteraAI Prostate Test now includes active surveillance, providing personalized insights into a patient’s risk of cancer progression. This helps clinicians and patients make informed decisions about monitoring prostate cancer, ensuring tailored care for those at low risk, while minimizing unnecessary treatments.

Research and Articles

"Why is PathNet worth it? [It's] better pathology."

Dr. Richard Bevan-Thomas, Urology Partners of North Texas

Interested in the ArteraAI Prostate Test?

12 + 6 =